Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the recipient of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 30,487,447 shares, a growth of 33.8% from the May 15th total of 22,785,221 shares. Based on an average daily trading volume, of 10,160,429 shares, the short-interest ratio is currently 3.0 days.

TEVA has been the topic of several research analyst reports. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $36.74 target price on the stock in a report on Tuesday, March 21st. Maxim Group reiterated an “outperform” rating and issued a $35.00 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, March 29th. Cowen and Company reissued an “outperform” rating and issued a $50.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, April 4th. BTIG Research reaffirmed a “neutral” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, April 6th. Finally, Oppenheimer Holdings, Inc. set a $43.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research report on Thursday, April 6th. Sixteen research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $43.51.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 3.89% during mid-day trading on Friday, hitting $31.90. The stock had a trading volume of 15,950,140 shares. The company has a market cap of $32.39 billion, a PE ratio of 6.21 and a beta of 0.47. The stock’s 50-day moving average is $30.42 and its 200 day moving average is $32.94. Teva Pharmaceutical Industries Limited has a 12 month low of $27.59 and a 12 month high of $55.79.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.06. The firm had revenue of $5.63 billion during the quarter, compared to analyst estimates of $5.69 billion. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The business’s quarterly revenue was up 17.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.20 earnings per share. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.78 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, June 22nd. Investors of record on Monday, June 5th were paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 4.26%. The ex-dividend date of this dividend was Thursday, June 1st. Teva Pharmaceutical Industries Limited’s payout ratio is presently 5,802.90%.

A number of institutional investors have recently made changes to their positions in TEVA. Sii Investments Inc. WI raised its position in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock worth $214,000 after buying an additional 25 shares during the last quarter. Salem Investment Counselors Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock worth $267,000 after buying an additional 32 shares during the last quarter. Cribstone Capital Management LLC increased its stake in shares of Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares during the period. Financial Architects Inc increased its stake in shares of Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock worth $143,000 after buying an additional 100 shares during the period. Finally, Sterling Investment Advisors Ltd. increased its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the period. 56.26% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/07/16/short-interest-in-teva-pharmaceutical-industries-limited-teva-expands-by-33-8-updated-updated-updated.html.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.